Inactive Instrument

Sensyne Health plc

Equities

SENS

GB00BYV3J755

Sensyne Health plc Appoints Dr. Ian Hudson to the Board as Independent Non-Executive Director with Effect from 28 June 2021

June 18, 2021 at 07:00 am

Sensyne Health plc announced the appointment of Dr. Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021. Dr. Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK's Medicines and Healthcare Products Regulatory Agency ("MHRA") between 2013 and 2019.

Latest news about Sensyne Health plc

E-Therapeutics plc Announces Strategic Collaboration with Arcturis Data Limited	11-02	CI
Cash-Strapped Sensyne Health to Lay Off Majority of Staff	27/04/22	MT
Sensyne Health Slumps 32% on End of Formal Sale Process, Planned Delisting	19/04/22	MT
Sensyne Health Ends Formal Sale Process With Expanded Note Purchase Agreement	19/04/22	MT
Sensyne Health Names New CEO	19/04/22	MT
Sensyne Health Announces Termination of the Formal Sale Process	19/04/22	CI
Sensyne Health Plummets 85% Amid CEO Change, Revised Financing Deal	08/04/22	MT
Sensyne Health Remains In Talks With Potential Buyers Amid Funding Increase To Continue Operating	08/04/22	MT
Sensyne Health CEO Steps Down; Successor Appointed	08/04/22	MT
Sensyne Health plc Announces Executive Changes	08/04/22	CI
Shares in Sensyne Dive After It Warns on Future, Amends Financing Agreement	08/04/22	DJ
Sensyne Health Issues New Shares To US Health Systems As Part Of Strategic Research Agreements	04/04/22	MT
Sensyne Health plc Announces Change in Registered Office	28/03/22	CI
Sensyne Health Issues Equity to Great Ormond Street Hospital for Children	18/03/22	MT
FTSE Flat, Activist Chatter Puts Vodafone Among FTSE 100 Leaders	31/01/22	DJ
Sensyne Health plc Reports Earnings Results for the Half Year Ended October 31, 2021	31/01/22	CI
Sensyne Health plc Announces Successful Completion of Financing	26/01/22	CI
Sensyne Health plc announced that it expects to receive £11.35 million in funding	25/01/22	CI
Sensyne Health CEO Mulls Delisting From London's AIM Segment	24/01/22	MT
FTSE 100 Closes 0.3% Lower as Royal Mail, B&M Plummet	14/01/22	DJ
FTSE Falls, Sterling Seen in Stable Range Vs Dollar in 2022	14/01/22	DJ
FTSE Down, GDP Data Seen Supporting Rate-Rise Bets But Pound Little Moved	14/01/22	DJ
Sensyne Health Down 67% As Formal Sale Process Moves Forward	14/01/22	MT
London Shares Edge Lower After Downbeat Asia Trading	14/01/22	DJ
Sensyne & Rwhealth Announces Sensight Partnership	24/12/21	CI

Chart Sensyne Health plc

Duration

Period

More charts

Company Profile

Sensyne Health plc is a United Kingdom-based clinical artificial intelligence company. The Company offers SENSIGHT platform, which provides a research environment for pharmaceutical and life science companies to analyze deidentified and anonymized patient data to support all stages of research and development. The Company applies clinical artificial intelligence (AI) in the healthcare and life science industries. In healthcare, the Company delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, the Company analyses anonymized data sets to help life sciences companies to develop medicines. The Company's healthcare products include a variety of applications, including decision-making support, remote patient monitoring, diagnostics, prescribed digital therapeutics and the recording and presentation of healthcare data in a clinical setting.

Sector

More about the company